Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $87

Benzinga · 12/22/2025 13:27
Barclays analyst Gena Wang maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $82 to $87.